BURLINGAME, Calif., July 6 /PRNewswire/ -- BioSeek, Inc., a leader in
applying integrated human biology systems for developing new therapeutics,
announced today that it has entered into a collaboration agreement with
GlaxoSmithKline (GSK). Under the collaboration, BioSeek will apply its
BioMAP(R) Systems for the characterization of compounds from GSK.
BioSeek's BioMAP(R) Systems are a series of human primary cell-based
assay systems designed to replicate the intricate cell and pathway
interactions present in human disease biology. Depending on their mechanism
of action, compounds induce specific patterns of changes in these systems
(BioMAP profiles) that can be compared to a large number of reference
profiles in BioSeek's database. BioMAP profiling can provide in-depth
characterization of drug function, including defining mechanism of action
and secondary activities, and can provide insights into potential clinical
applications.
"We are excited to be working closely with the innovative scientific
teams in GSK as we continue to demonstrate the utility of BioMAP Systems to
drive drug discovery," commented Peter Staple, chief executive officer of
BioSeek. "This collaboration will enable us to make use of the full range
of applications of our technology."
Financial terms of the agreement were not disclosed.
About BioSeek
BioSeek is improving the success rate of pharmaceutical research and
development by integrating human biology from the early stages of drug
discovery onward. The Company's BioMAP(R) Systems incorporate predictive
human cell-based disease models that generate uniquely informative activity
signatures for each potential drug, driving the selection and development
of new drug candidates. BioSeek is leveraging BioMAP(R) Systems technology
in collaborations to enhance the productivity of its pharmaceutical
partners' pipelines, and in the Company's internal programs to identify
promising compounds for proprietary development in the fields of
inflammation, cardiovascular diseases, autoimmune diseases and related
indications.
For more information, go to http://www.bioseekinc.com
Contacts:
BioSeek, Inc.
Peter D. Staple, Chief Executive Officer
Tel: 650.552.0751
E-mail: pstaple@bioseekinc.com
MacDougall BioMedical Communications
Kari Watson
Tel: 508.647.0209
E-mail: kwatson@macbiocom.com
SOURCE BioSeek, Inc.
 back to top
Related links:
http://www.bioseekinc.com
CONTACT:
Peter D. Staple, Chief Executive Officer of
BioSeek, Inc., +1- 650-552-0751, pstaple@bioseekinc.com; or Kari
Watson of MacDougall BioMedical Communications, +1-508-647-0209,
kwatson@macbiocom.com
|
